New Counterpart Health whitepaper finds patients whose primary care physicians (PCP) used Counterpart Assistant’s flu-related clinical insight were 1.89 times more likely to receive a flu vaccination — and patients with COPD and CHF experienced significantly fewer flu-related hospitalizations and
Clover Health's early adoption of real-time patient access to claims data on Kno2 is made possible by underlying infrastructure powered by Counterpart Health NOTICE: This is an updated version of a press release originally issued March 4, 2026 by Clover Health Investments, Corp. (Nasdaq: CLOV).
Business Highlights: Generated full year 2025 Adjusted EBITDA profitability while growing membership by 38% and Insurance revenue by 41% year-over-year Achieved industry-leading 2026 AEP growth of 53% year-over-year with strong returning member retention Expect improving cohort economics powered by
WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Leerink 2026 Global Healthcare Conference on Tuesday, March 10,
WILMINGTON, Del., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Thursday, February 26, 2026.
Clover delivers market-leading Medicare Advantage growth, establishing a strong path to achieve its first-ever full year GAAP Net Income profitability in 2026. Disciplined, core-market growth, strong returning member retention, and improving cohort economics position Clover for compounding earnings
Counterpart continues to demonstrate that unified data and real-time insights, delivered directly into the clinician’s workflow, drive measurable clinical and financial outcomes SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Counterpart Health , Inc. (“Counterpart” or the “Company”), a leading
